The MDMA study was her last hope. She had read headlines celebrating a 83% response rate in one small, early study of the psychedelic for treating PTSD, and was counting on the new clinical trial to alleviate her own post-traumatic stress disorder. Instead, after her first MDMA session, she felt intense despair when her symptoms didn’t dissipate.
She described standing on a train platform, while on the phone with her study therapists, and considering jumping in front of a train, according to a video of the participant describing the experience at a 2016 conference on psychedelic therapy that STAT has seen. “For the first time in a really long time I went, ‘I am done,’” she told the audience. “All that is pounding through my head is: ‘Why am I not that 83%?’”
In the end, the study participant, who STAT isn’t identifying to protect her personal medical information, told herself she couldn’t jump; she said she worried that doing so would be marked as an adverse event and risk threatening the success of the MDMA research — which was a crucial step in efforts to seek Food and Drug Administration approval of the drug. Suicidal ideation itself should be counted as an adverse event, said Philip Corlett, a psychiatry professor at Yale University. But the incident doesn’t seem to be reflected in the published data from the trial on clinicaltrials.gov, the government registry of studies and their outcomes.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect